However, our RNA-seq analysis revealed that it was not GLI1 but rather GLI2 and GLI3 that were activated in paclitaxel-resistant NSCLC cells, potentially due to alterations in the tumor microenvironment. The gene discussed is GLI1; the disease is non-small cell lung carcinoma.